New drug combo aims to control Hard-to-Treat myeloma
NCT ID NCT07217119
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This study tests a combination of two drugs, belantamab mafodotin and feladilimab, in about 25 adults with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goals are to check safety and find the best dose. This is not a cure, but aims to help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Atlanta, Georgia, 30322, United States
-
GSK Investigational Site
Madison, Wisconsin, 53792, United States
-
GSK Investigational Site
Fitzroy, Victoria, 3065, Australia
-
GSK Investigational Site
Melbourne, Victoria, 3000, Australia
-
GSK Investigational Site
Vancouver, British Columbia, V5Z1M9, Canada
-
GSK Investigational Site
Toronto, Ontario, M5G2M9, Canada
-
GSK Investigational Site
Villejuif, 94805, France
-
GSK Investigational Site
Hamburg, 22083, Germany
-
GSK Investigational Site
Utrecht, 3584CX, Netherlands
-
GSK Investigational Site
Pamplona Navarra, 31008, Spain
-
GSK Investigational Site
Stockholm, SE-141 86, Sweden
Conditions
Explore the condition pages connected to this study.